Diagnostic and prognostic utility of molecular markers in synchronous bilateral breast carcinoma.
Histologic criteria have a limited role in determining whether the synchronous bilateral breast carcinomas represent two primaries or a metastasis to the contralateral breast. We studied the molecular analysis of synchronous bilateral breast carcinoma and whether they are originating from a single or different clone. We examined 17 patients with breast carcinoma, including 12 patients with synchronous bilateral carcinomas and control group of 5 infiltrating ductal carcinomas with regional lymph node metastases. Mutations were quantitatively determined to detect loss of heterozygosity (LOH) and microsatellite size alterations for a broad panel of 15 markers, involving 10 chromosomes using polymerase chain reaction. The carcinomas were classified as de novo or metastasis based on three levels of concordance: (1) marker-affected tumors were considered concordant if 50% or more of the same markers were mutated, (2) same gene copy affected, and (3) temporal sequence of mutation acquisition. In synchronous bilateral breast carcinoma patients, molecular analysis showed discordant mutations in all cases, supporting the diagnosis of de novo bilateral primary breast carcinomas. In patients with lymph node metastases, the primary breast carcinoma and metastases shared the same mutations, revealing a metastatic lesion. In conclusion, the application of molecular technology may play an important role for the differential diagnosis of dual primary carcinomas vs a metastatic breast cancer to contralateral breast. In this study, synchronous bilateral breast cancers represent two independent primaries rather than metastatic events.
Saad
Reda S
RS
Department of Pathology, Allegheny General Hospital/Drexel University College of Medicine, Pittsburgh, PA 15212, USA. rsaad@wpahs.org
Denning
Krista L
KL
Finkelstein
Sydney D
SD
Liu
Yulin
Y
Pereira
Telma C
TC
Lin
Xiaoqi
X
Silverman
Jan F
JF
D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D001943:Breast Neoplasms / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D018270:Carcinoma, Ductal, Breast / Q000235:genetics* / Q000378:metabolism / Q000556:secondary; D004252:DNA Mutational Analysis; D005260:Female; D005819:Genetic Markers / Q000235:genetics*; D006801:Humans; D019656:Loss of Heterozygosity; D008207:Lymphatic Metastasis; D008408:Mastectomy; D018895:Microsatellite Repeats; D008875:Middle Aged; D009378:Neoplasms, Multiple Primary / Q000235:genetics* / Q000378:metabolism / Q000473:pathology; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011987:Receptors, Steroid / Q000378:metabolism
D014408:Biomarkers, Tumor; D005819:Genetic Markers; D018719:Erb-b2 Receptor Tyrosine Kinases; D011987:Receptors, Steroid